Results 31 to 40 of about 8,469 (207)

Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1

Frontiers in Endocrinology, 2019
Context: Overall, giant prolactinomas are rare tumors (4%), especially those larger than 60 mm (1%). Despite the predominance of macroadenoma documented in multiple endocrine neoplasia type 1 (MEN1)-related prolactinoma, only three giant prolactinoma ...
Naiara C. B. Dantas, Carlos E. L. Soares, Manoel R. A. Martins, Delmar M. Lourenço, Delmar M. Lourenço, Ana R. P. Quidute, Ana R. P. Quidute   +6 more
doaj   +1 more source

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

BMC Endocrine Disorders, 2021
Background Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal.
Yunzhi Zou, Depei Li, Jiayu Gu, Siyu Chen, Xia Wen, Jiajun Dong, Xiaobing Jiang   +6 more
doaj   +1 more source

A Novel Case of Spontaneous Coronary Artery Dissection During Cabergoline Therapy for Prolactinoma

JACC: Case Reports, 2020
We present a case of spontaneous coronary artery dissection associated with cabergoline treatment for prolactinoma. A 31-year-old woman with history of hypertension and prolactinoma, treated with cabergoline, presented with chest pain.
Shinichiro Ikeda, MD, Jeffrey Le, MD, Shivani Verma, MD, Benjamin A. Youdelman, MD   +3 more
doaj   +1 more source

Clinical characteristics and presence of prolactinoma in women with hyperprolactinemia

Iatreia, 2016
Objectives: To clinically characterize women with hyperprolactinemia at InSer Pereira (Colombia) and to determine the prevalence of prolactinoma. Methods: Retrospective description of 45 patients with hyperprolactinemia, and contrasted pituitary magnetic
López-Clavijo, Carlos Alberto, Gaviria-Maya, Juan Esteban, Henao-Flórez, Rodrigo Eduardo, Piedrahíta-Gutiérrez, Dany Leandro   +3 more
doaj   +1 more source

Aggressive giant prolactinoma: a case report

Journal of Medical Case Reports, 2022
Background Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.
Marisa Khatijah Borhan, Florence Hui Sieng Tan   +1 more
doaj   +1 more source

Identification of potential and novel target genes in pituitary prolactinoma by bioinformatics analysis

AIMS Neuroscience, 2021
Pituitary prolactinoma is one of the most complicated and fatally pathogenic pituitary adenomas. Therefore, there is an urgent need to improve our understanding of the underlying molecular mechanism that drives the initiation, progression, and metastasis
Vikrant Ghatnatti , Basavaraj Vastrad, Swetha Patil , Chanabasayya Vastrad, Iranna Kotturshetti   +4 more
doaj   +1 more source

A giant invasive macroprolactinoma with recurrent nasal bleeding as the first clinical presentation: case report and review of literature

BMC Endocrine Disorders, 2023
Background Giant prolactinoma (> 4 cm in dimension) is a rare disorder. Invasive macroprolactinoma has the potential to cause base of skull erosion and extend into the nasal cavity or even the sphenoid sinus.
Danting Li, Yan Wang, Huiwen Tan, Peiqiong Luo, Yerong Yu   +4 more
doaj   +1 more source

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

Andrology, EarlyView.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret, Aaran H. Patel, Elisabeth Daniels, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report

Journal of Medical Case Reports, 2019
Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi, Yukiko Nakahara, Ryo Ebashi, Atsushi Ogata, Shoko Shimokawa, Jun Masuoka, Tatsuya Abe   +6 more
doaj   +1 more source

Pharmacokinetics and adverse effects of a long‐acting IM dopamine agonist: Cabergoline in healthy horses

Equine Veterinary Education, EarlyView.
Summary Background Pituitary pars intermedia dysfunction (PPID) is commonly treated with pergolide mesylate, a dopamine receptor agonist. Cabergoline is a dopamine receptor agonist that has shown activity on prolactin secretion in horses for up to 10 days.
H. Hess, A. Bracken, S. Rao, Y. Nout‐Lomas, D. Gustafson, L. Bass   +5 more
wiley   +1 more source